Abstracts Archive - Page 2225 of 2605 - ACR Meeting Abstracts

Abstract Number: 101 • 2014 ACR/ARHP Annual Meeting
Country of Residence and Its Wealth Determine Disease Activity Levels in RA: Results from Multi-National Study Across 17 Countries (COMORA)
Polina Putrik^1,2, Sofia Ramiro³, Andras Keszei⁴, Ihsane Hmamouchi⁵, Maxime Dougados⁶, Till Uhlig⁷, Tore K. Kvien⁷ and Annelies Boonen⁸, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Health Promotion, Maastricht University, Maastricht, Netherlands, ³Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ⁴Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ⁵Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁶Cochin Hospital, Paris Descartes University, Paris, France, ⁷Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose Socio-economic (SE) inequalities in health persist both between and within countries and even increased in the recent years. Therefore, it is important to explore…
Abstract Number: 100 • 2014 ACR/ARHP Annual Meeting
Evaluation of Real World Experience with Non-Biologic DMARD in the Treatment of RA: Data from an Electronic Health Record Database
D. Wiederkehr¹, J. Harnett¹, R. Gerber², D. Gruben², E.Y. Mahgoub³, G. Wallenstein¹ and A. Koenig³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Non-biologic (NB) disease-modifying antirheumatic drugs (DMARD) such as methotrexate (MTX) are commonly used to treat rheumatoid arthritis (RA). However, NB‑DMARD can have adverse events…
Abstract Number: 99 • 2014 ACR/ARHP Annual Meeting
Impact of Comorbidities on Health Resource Utilization in Patients with Spa
Mariano Andrés¹, Francisca Sivera², Sabina Pérez-Vicente³, Loreto Carmona⁴ and Paloma Vela^1,5, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ³Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, ⁴Instituto de Salud Musculoesquelética, Madrid, Spain, ⁵Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Similar to other rheumatic disorders, patients with spondyloarthritis (SpA) show an increased prevalence of comorbidities compared to the general population [1]. Comorbidities influence management,…
Abstract Number: 102 • 2014 ACR/ARHP Annual Meeting
Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom
Frances Humby¹, Stephen Kelly¹, Angela V. Bedenbaugh², Nawab Qizilbash^3,4, Jochen Dunkel⁵, Belén SanJose³, Ignacio Mendez³, Jennifer Timoshanko⁶ and Jeyanesh Tambiah², ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²UCB Pharma, Smyrna, GA, ³OXON Epidemiology, London, United Kingdom, ⁴Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Slough, United Kingdom
Background/Purpose Several anti-TNFs are currently approved in Europe for RA treatment including certolizumab pegol (CZP), adalimumab (ADA), etanercept (ETN), golimumab and infliximab. UK NICE guidance…
Abstract Number: 107 • 2014 ACR/ARHP Annual Meeting
Use of Internet in Adolescents and Young Adults with JIA
Philomine A. van Pelt¹, Constance H.C. Drossaert², Radboud JEM Dolhain³, A.a. Kruize⁴, Jaap Huisman⁵ and Nico Wulffraat⁶, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Psychology, Health and Technology, University of Twente, Enschede, Netherlands, ³Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pediatric Psychology, Wilhelmina's Children Hospital UMC Utrecht, Utrecht, Netherlands, ⁶Paediatric Immunology and Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose Internet-use is increasing since it is an efficient way to find information. Information obtained via Health Related Internet (HRI) sites, or online peer support…
Abstract Number: 80 • 2014 ACR/ARHP Annual Meeting
Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry
Michael Kruse Meyer¹, Marlene Andersen², Grethe N. Andersen¹ and Allan Stensballe³, ¹Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, ²Department of Rheumatology, Aalborg University, Hjørring, Denmark, ³Health Science and Technology, Aalborg University, Aalborg, Denmark
Background/Purpose: In this study we are analyzing leukocyte subtype responses from patients with rheumatoid arthritis (RA) to IL6 inhibition. A large contribution to RA immunopathogenesis…
Abstract Number: 79 • 2014 ACR/ARHP Annual Meeting
PECAM-1 GENE Polymorphisms and Soluble PECAM-1 LEVEL in Rheumatoid Arthritis and Systemic LUPUS Erythematosus Patients Is There a Link with Clinical Atherosclerotic Events?
Omer Nuri Pamuk¹, Hilmi Tozkir², Mehmet Sevki Uyanik³, Hakan Gurkan⁴, Julide Duymaz⁴, Salim Donmez⁵, Metin Yazar² and Gulsum Pamuk³, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Genetics, Trakya University Medical Faculty, EDIRNE, Turkey, ³Hematology, Trakya University Medical Faculty, Edirne, Turkey, ⁴Trakya University Medical Faculty, EDIRNE, Turkey, ⁵Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey
Background/Purpose: Platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) which plays a role in the transmigration of leucocytes into tissues is a member of the immunoglobulin (Ig) superfamily.…
Abstract Number: 78 • 2014 ACR/ARHP Annual Meeting
a HPLC-SRM-MS Based Method for the Detection and Quantification of Methotrexate Used at Doses in Clinical Practice for Patients with Rheumatological Disease in Urine
James Bluett¹, Isabel Riba-Garcia², Richard Unwin², Suzanne Verstappen³ and Anne Barton^4,5, ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom
Background/Purpose Methotrexate (MTX) is a recommended first-line therapy in 2013 EULAR guidelines for active rheumatoid arthritis (RA). Despite this, up to 54% do not adequately…
Abstract Number: 77 • 2014 ACR/ARHP Annual Meeting
Epigenome Profiling Reveals Robust Hypomethylation of Interferon Signature Genes in Lupus Neutrophils
Patrick Coit¹, Sri Yalavarthi¹, Wenpu Zhao², Mariana J. Kaplan² and Amr H. Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Lupus neutrophils play an important role in tissue damage (including glomerulonephritis and lupus skin involvement), as well as endothelial damage in lupus patients. Several…
Abstract Number: 96 • 2014 ACR/ARHP Annual Meeting
Comparison of Cardiovascular Risk Factor Management in Patients with RA and Matched Non-RA Patients
H Cawston¹, E Alemao², F Bourhis¹, T Le³, M Al⁴, M Rutten-van Molken⁴, Katherine Liao⁵ and DH Solomon⁶, ¹OptumInsight, Nanterre, France, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Hopewell, NJ, ⁴Erasmus University, Rotterdam, Netherlands, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose : The relative risk of acute myocardial infarction in RA patients (pts) has been shown to range from 1.5 to 2.0, with a 1.4–2.7-fold…
Abstract Number: 95 • 2014 ACR/ARHP Annual Meeting
Comparison of Patient Characteristics, Healthcare Costs, and Biologic Persistence Between Patients with Rheumatoid Arthritis Initiating First- or Second-Line Subcutaneous Abatacept, Adalimumab, or Etanercept
S Johnston¹, F Lobo², D McMorrow¹, R Fowler¹, D Smith¹ and A Nadkarni², ¹Truven Health Analytics, Bethesda, MD, ²Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: There are currently very limited comparative published data on the characteristics, healthcare costs, and biologic persistence among patients with RA who have been treated…
Abstract Number: 94 • 2014 ACR/ARHP Annual Meeting
Possible Effects of Medicare-Only Insurance Coverage on the Use of Biologics in Patients with RA
Marcia Genta, Dallas Arthritis Center, Dallas, TX
Background/Purpose: Biologics, a relatively new widely used class of medication that can substantially improve the course of RA, are expensive and their use is not…
Abstract Number: 93 • 2014 ACR/ARHP Annual Meeting
Protein Profiling of Secretome Human Cartilage to Identify Potential EARLY Specific Biomarkers in Osteoarthritis
Lucia Lourido, Valentina Calamia, Patricia Fernandez-Puente, Jesus Mateos, Francisco J. Blanco Garcia, Beatriz Rocha, Carolina Fernández-Costa, Carlos Fernandez-Lopez, Natividad Oreiro and Cristina Ruiz-Romero, Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain
Background/Purpose: Osteoarthritis (OA) is characterized by the progressive loss of cartilage structural extracellular matrix (ECM) components. The release of these proteins from the tissue can…
Abstract Number: 92 • 2014 ACR/ARHP Annual Meeting
Long Noncoding RNA Nron Regulates the Activity of NFAT5 through Ubiquitin-Independent Proteasome Pathway in Rheumatoid Arthritis
Kunihiko Umekita^1,2, Michelle Trenkmann¹, Christoph Kolling³, Akihiko Okayama⁴, Renate Gay¹, Steffen Gay¹ and Mojca Frank Bertoncelj⁵, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Department of Rheumatology, Infectious diseases and Laboratory medicine, University of Miyazaki, Miyazaki, Japan, ³Schulthess Clinic, Zurich, Switzerland, ⁴Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, ⁵Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Long noncoding RNAs (lncRNAs) are increasingly recognized as master regulators of gene expression. The lncRNA NRON, noncoding repressor of nuclear factor of activated T…
Abstract Number: 91 • 2014 ACR/ARHP Annual Meeting
Quantitative Proteomics Using Dimethyl Isotope Labeling for Comparison of Fresh Frozen Versus Formalin-Fixed, Paraffin-Embedded Tissue for Lupus Nephritis
Abhimanyu Amarnani¹, Joseph Capri², Puneet Souda³, David Elashoff⁴, Ivan Lopez⁵, Julian Whitelegge³ and Ram Singh¹, ¹Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²Pasarow Mass Spectrometry Laboratory, University of California, Los Angeles, Los Angeles, CA, ³The Pasarow Mass Spectrometry Laboratory, University of California, Los Angeles, Los Angeles, CA, ⁴Medicine/Statistics Core, University of California, Los Angeles, Los Angeles, CA, ⁵Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA
Background/Purpose Lupus nephritis (LN) progresses from mild focal inflammation, to diffuse proliferative nephritis, to fibrosis and end-stage renal disease. Though the understanding of LN has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].